Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes

Figure 3

(a) 4T1 TDLNs transferred into BALB/c mice. BALB/c mice bearing 3-day established 4T1 subcutaneous tumors treated with 4T1 TDLNs (Lo AIT) were cured of tumor while those treated with HBSS (control) died of metastatic disease. Each line represents one mouse (). (b) CD4/CD8 depleted TDLNs into BALB/c mice. BALB/c mice with 4T1 subcutaneous tumors were treated with 4T1 TDLNs depleted of CD4 or CD8 cells. Therapeutic efficacy of transferred TDLN appears to be primarily related to intact CD4. Each line represents one mouse (). (c) 4T1 TDLNs transferred into SCID mice. SCID mice bearing 3-day established 4T1 subcutaneous tumors treated with 4T1 TDLNs and control mice all died, suggesting the need for some immune competence in the tumor-bearing mice for tumorigenicity of transferred TDLNs. Each line represents one mouse (). (d) 4T1 TDLNs transferred into Rag2−/− mice. Rag2−/− mice bearing 3-day established 4T1 subcutaneous tumors were treated with HBSS (CTRL, ) or 4T1 TDLNs (Lo AIT, ). Results suggest that NK cells within the tumor-bearing host are necessary for therapeutic activity of transferred TDLN. Each line represents one mouse.

(a)

(b)

(c)

(d)